Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches of AGAMREE® (vamorolone).

The agreement was initially secured in September 2025 with R-Bridge, an affiliate of CBC Group, covering 25% of net royalties on AGAMREE from Catalyst Pharmaceuticals, Inc. in North America and Sperogenix Therapeutics Ltd in China. Since initially securing the agreement, Partners Group, one of the largest firms in the global private markets industry, has joined the financing, contributing a majority of the USD 13 million raised.

Payments to Partners Group and R-Bridge are capped. Once the agreed ceiling or duration is reached, North American and Chinese royalties revert to Santhera. Santhera retains buy-back rights over the royalty stream. Under an additional agreement secured with R-Bridge in 2024, R-Bridge is entitled to 75% of net royalties from Catalyst and Sperogenix.

Dario Eklund, Chief Executive Officer of Santhera, said: “We are pleased to announce the closing of this royalty monetization agreement, now with the addition of Partners Group. This provides important growth capital to support our strategy and global rollout of AGAMREE.”